Technical Analysis for CERC - Cerecor Inc.

Grade Last Price % Change Price Change
F 2.61 -4.04% -0.11
CERC closed down 4.04 percent on Tuesday, April 13, 2021, on 1.65 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CERC trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish -4.04%
Down 3 Days in a Row Weakness -4.04%
Lower Bollinger Band Touch Weakness -4.04%
Older End-of-Day Signals for CERC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
3x Volume Pace about 15 hours ago
2x Volume Pace about 15 hours ago
1.5x Volume Pace about 15 hours ago
Down 5% about 15 hours ago
Down 3% about 15 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Cerecor Inc. Description

Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406 for the treatment of residual cognitive impairment symptoms in patients with MDD. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor, Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disorders Symptoms Organic Chemistry Major Depressive Disorder Depressive Disorder Depression Echo Piperidines Antidepressants Psychiatric Disorders Pyrrolidines Cognitive Impairment Nmda Receptor Antagonists Substance Use Disorder

Is CERC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 4.49
52 Week Low 1.97
Average Volume 671,119
200-Day Moving Average 2.76
50-Day Moving Average 3.36
20-Day Moving Average 3.02
10-Day Moving Average 2.91
Average True Range 0.23
ADX 14.4
+DI 22.55
-DI 26.95
Chandelier Exit (Long, 3 ATRs ) 2.85
Chandelier Exit (Short, 3 ATRs ) 3.13
Upper Bollinger Band 3.41
Lower Bollinger Band 2.63
Percent B (%b) -0.03
BandWidth 25.87
MACD Line -0.15
MACD Signal Line -0.12
MACD Histogram -0.0265
Fundamentals Value
Market Cap 195.49 Million
Num Shares 74.9 Million
EPS -0.89
Price-to-Earnings (P/E) Ratio -2.92
Price-to-Sales 25.91
Price-to-Book 5.04
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.02
Resistance 3 (R3) 3.01 2.86 2.95
Resistance 2 (R2) 2.86 2.76 2.87 2.92
Resistance 1 (R1) 2.74 2.70 2.67 2.75 2.90
Pivot Point 2.59 2.59 2.56 2.60 2.59
Support 1 (S1) 2.47 2.49 2.40 2.48 2.32
Support 2 (S2) 2.32 2.43 2.33 2.30
Support 3 (S3) 2.20 2.32 2.27
Support 4 (S4) 2.21